PMID- 22842485
OWN - NLM
STAT- MEDLINE
DCOM- 20131231
LR  - 20220330
IS  - 1791-2423 (Electronic)
IS  - 1019-6439 (Linking)
VI  - 41
IP  - 4
DP  - 2012 Oct
TI  - Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human 
      vascular endothelial growth factor receptor 1 and 2 in patients with advanced 
      gastric cancer.
PG  - 1297-304
LID - 10.3892/ijo.2012.1573 [doi]
AB  - The aim of this study was to evaluate the safety and efficacy of vaccination with 
      human leukocyte antigen (HLA)-A24-restricted human vascular endothelial growth 
      factor receptor 1 (VEGFR1)-1084 and VEGFR2-169 combined with chemotherapy in 
      patients with advanced gastric cancer. HLA-A 2402-positive patients with advanced 
      or recurrent adenocarcinoma of the stomach were vaccinated with VEGFR1-1084 and 
      VEGFR2-169 combined with S-1 and cisplatin. The study included 22 patients 
      (median age 60.5 years) who received at least one cycle of the combination 
      therapy. No severe adverse effects caused by the vaccine therapy were observed 
      except for an inflammatory reaction at the site of injection in 6 patients. 
      Twelve patients (55%) showed partial response and 10 had stable disease after two 
      cycles of the combination therapy. The disease control rate (partial response and 
      stable disease) was 100% after two cycles. The median time to progression was 9.6 
      months and median overall survival was 14.2 months. VEGFR1-1084-specific 
      cytotoxic T lymphocyte (CTL) response was induced in 18 (82%) of the 22 patients 
      and VEGFR2-169-specific CTL response was induced in 18 (82%) of the 22 patients. 
      Patients showing CTL response to VEGFR2-169 peptide had significantly better 
      prognosis than those without, as demonstrated by the overall survival (OS) and 
      time to progression (TTP) (OS, p=0.028, TTP, p=0.006). The combination therapy 
      was well tolerated and highly effective in advanced or recurrent gastric cancer. 
      Substantial specific CTL for both peptides was frequently induced even under 
      chemotherapy. Thus, cancer vaccination combined with standard chemotherapy 
      warrants further analysis as a promising strategy for the treatment of advanced 
      cancer.
FAU - Masuzawa, Toru
AU  - Masuzawa T
AD  - Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka 
      University, Suita, Osaka, Japan.
FAU - Fujiwara, Yoshiyuki
AU  - Fujiwara Y
FAU - Okada, Kaoru
AU  - Okada K
FAU - Nakamura, Ayumu
AU  - Nakamura A
FAU - Takiguchi, Shuji
AU  - Takiguchi S
FAU - Nakajima, Kiyokazu
AU  - Nakajima K
FAU - Miyata, Hiroshi
AU  - Miyata H
FAU - Yamasaki, Makoto
AU  - Yamasaki M
FAU - Kurokawa, Yukinori
AU  - Kurokawa Y
FAU - Osawa, Ryuji
AU  - Osawa R
FAU - Takeda, Kazuyoshi
AU  - Takeda K
FAU - Yoshida, Koji
AU  - Yoshida K
FAU - Tsunoda, Takuya
AU  - Tsunoda T
FAU - Nakamura, Yusuke
AU  - Nakamura Y
FAU - Mori, Masaki
AU  - Mori M
FAU - Doki, Yuichiro
AU  - Doki Y
LA  - eng
PT  - Clinical Trial, Phase I
PT  - Clinical Trial, Phase II
PT  - Journal Article
DEP - 20120725
PL  - Greece
TA  - Int J Oncol
JT  - International journal of oncology
JID - 9306042
RN  - 0 (Cancer Vaccines)
RN  - 0 (Drug Combinations)
RN  - 0 (HLA-A*24:02 antigen)
RN  - 0 (HLA-A24 Antigen)
RN  - 0 (Vaccines, Subunit)
RN  - 150863-82-4 (S 1 (combination))
RN  - 1548R74NSZ (Tegafur)
RN  - 5VT6420TIG (Oxonic Acid)
RN  - EC 2.7.10.1 (Vascular Endothelial Growth Factor Receptor-1)
RN  - EC 2.7.10.1 (Vascular Endothelial Growth Factor Receptor-2)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Adenocarcinoma/drug therapy/pathology
MH  - Aged
MH  - Cancer Vaccines/administration & dosage
MH  - Cisplatin/administration & dosage
MH  - Combined Modality Therapy
MH  - Drug Combinations
MH  - Female
MH  - HLA-A24 Antigen/genetics/immunology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Oxonic Acid/administration & dosage
MH  - Prognosis
MH  - Stomach Neoplasms/*drug therapy/immunology/pathology
MH  - T-Lymphocytes, Cytotoxic/immunology/pathology
MH  - Tegafur/administration & dosage
MH  - Vaccines, Subunit/*administration & dosage/genetics/immunology
MH  - Vascular Endothelial Growth Factor Receptor-1/*genetics/immunology/therapeutic 
      use
MH  - Vascular Endothelial Growth Factor Receptor-2/*genetics/immunology/therapeutic 
      use
EDAT- 2012/07/31 06:00
MHDA- 2014/01/01 06:00
CRDT- 2012/07/31 06:00
PHST- 2012/03/24 00:00 [received]
PHST- 2012/05/22 00:00 [accepted]
PHST- 2012/07/31 06:00 [entrez]
PHST- 2012/07/31 06:00 [pubmed]
PHST- 2014/01/01 06:00 [medline]
AID - 10.3892/ijo.2012.1573 [doi]
PST - ppublish
SO  - Int J Oncol. 2012 Oct;41(4):1297-304. doi: 10.3892/ijo.2012.1573. Epub 2012 Jul 
      25.